TRAW (Traws Pharma) FFO


TRAW Traws Pharma Inc TRAW
49 GF Score
Price $0.83
GF Value $12.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma FFO?

FFO (Funds from operations) only applies to REITs.

TRAW
49GF Score
Traws Pharma Inc TRAW
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.83 is trading 93.6% below its estimated GF Value™ of $12.92. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • FFO:
  • GF Value™: $12.92 vs. price of $0.83 (93.6% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
49GF Score

Get the complete analysis for TRAW

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price
$12.92
GF Value